Ajanta Pharma Ltd operates seven finished dose manufacturing facilities that manufacture high quality generics across a broad array of dosage forms, including tablets, capsules, ointments, powders and sterile eye drops.

US Food and Drug Administration (FDA) has approved 2 of Ajanta’s facilities, one of them being flagship finished oral solid dosage facility in Aurangabad, India also approved by World Health Organization pre-qualification and various other regulatory agencies throughout the world.

The 2nd one is a new oral solid dosage facility in Dahej, India employing the latest state of the art equipment and procedures which was successfully approved by US FDA in August 2017. To ensure adequate capacities and cater to Company's growth in coming years, the company always proactively invest in its manufacturing capabilities. In January 2017 company has operationalized another formulations manufacturing facility in India to serve domestic and emerging markets.

Company’s robust process development and proprietary technology across various product platforms ensures Ajanta is producing high quality products efficiently.